ALLSTARNCT07791043
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 13 → 17 locations
- Minor Study sites: 13 to 14
- Minor Trial sites expanded: 4 → 13 locations
- Minor Study sites: 3 to 4
Notable Recruitment opened Show 5 more changesShow less
- Eligibility criteria expanded, about 27 words
- Trial sites expanded: 0 → 3 locations
- Primary completion date: Sep 5, 2028 to Aug 11, 2028
- Study completion date: Feb 6, 2030 to Jan 14, 2030
- Start date changed from estimate of Sep 23, 2026 to Aug 31, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from Baseline in vibration-controlled transient elastography-liver stiffness measurement (VCTE-LSM)
Timeframe: Baseline (Day 1) and up to Week 60
Change from Baseline in model for end-stage liver disease (MELD) score
Timeframe: Baseline (Day 1) and up to Week 60
Secondary (11)
Change from Baseline in serum aspartate aminotransferase (AST) (International units per liter)
Change from Baseline in a blood test that helps predict the risk of disease progression in liver disease
Trough Concentration at steady state (Ctrough,ss) following administration of efimosfermin alfa
Area Under the concentration-time Curve from Time 0 (pre-dose) to the last quantifiable concentration (AUC[0-t]) of efimosfermin alfa in the subset of participants with optional intensive pharmacokinetics (PK) sampling
Maximum observed drug concentration (Cmax) of efimosfermin alfa in the subset of participants with optional intensive PK sampling
Show 6 moreShow less
Number of Participants with Anti-drug antibodies (ADA) against efimosfermin alfa
Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severity
Number of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Number of participants with clinically significant changes in Vital signs
Number of participants with clinically significant changes in 12-lead electrocardiogram (ECG) findings
Arms and interventions
Efimosfermin alfa Dose Level 1Experimental
Participants will receive efimosfermin alfa dose level 1.
Efimosfermin alfa Dose Level 2Experimental
Participants will receive efimosfermin alfa dose level 2.
Efimosfermin alfa Dose Level 3Experimental
Participants will receive efimosfermin alfa dose level 3.
PlaceboPlacebo comparator
Participants will receive placebo.
Drugs: Efimosfermin alfa, Placebo
Sites
17 sites in 5 countries
Argentina 5, United States 5, South Korea 4, Greece 2, Canada 1